PR Newswire BiotechOriginal article
Rigel Highlights New GAVRETO® (pralsetinib) Data Across RET Fusion-Positive Cancers in Oral and Poster Presentations at ESMO Congress 2026
ConferencepositiveGAVRETOPositive
AI Analysis
Summary
Rigel presented new GAVRETO (pralsetinib) data at ESMO Congress 2026, including a pooled ARROW and TAPISTRY analysis showing a 53% overall response rate in RET fusion-positive solid tumors. Additional analyses covered first-line outcomes and quality of life in RET fusion-positive NSCLC.
Clinical Trial Data
Outcome Details
Pooled ARROW and TAPISTRY analysis showed a 53% overall response rate in patients with RET fusion-positive solid tumors; additional analyses presented on first-line outcomes and patient-reported quality of life in RET fusion-positive NSCLC.
Importance:5/10
Sentiment:
0.50
ESMO 2026GAVRETOpralsetinibRET fusionNSCLCsolid tumorsoncologyARROWTAPISTRYconference presentation
Related Companies
Read the original article
Published by PR Newswire Biotech on October 19, 2026 12:05 PM